Unfavorable IL-28 Genotype Benefits from the GI-5005 Hep C Vaccine | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

A Vaccine Plus Antiviral Meds Could Conquer Hepatitis C

Back to News Homepage
Next

Differentiating Between Hepatitis C Genotypes and the IL-28B Genotype

Unfavorable IL-28 Genotype Benefits from the GI-5005 Hep C Vaccine

The Editors at Hepatitis Central
December 7, 2010

Print this page

When added to conventional antiviral therapy, GlobeImmune’s investigational, therapeutic Hepatitis C vaccine appears to correct a fundamental deficit in cellular immunity in those with the disadvantaged T/T allele of the IL-28 gene.

Hepatitis C Vaccine Elicits Immune Response in Some Patients

By: Diana Mahoney, Internal Medicine News Digital Network

BOSTON – A therapeutic vaccine against the hepatitis C virus was associated with a significantly higher sustained virologic response rate when added to standard-of-care treatment, and the findings justify further development of the vaccine, Dr. Paul Pockros reported at the annual meeting of the American Association for the Study of Liver Diseases.

In the proof-of-concept trial, 133 patients infected with hepatitis C virus (HCV) genotype 1 were randomized to either triple therapy comprising the experimental GI-5005 vaccine, which is designed to elicit a T-cell response specific to HCV, along with pegylated interferon alfa-2b plus ribavirin (P/R), or the standard P/R therapy alone.

Continue reading this entire article:
http://www.ehospitalistnews.com/topics/gastroenterology/single-article-page/hepatitis-c-vaccine-elicits-immune-response-in-some-patients/86315a963a564b69a44cd6c7ee91a7f0.html

No Comments - be the first!
Share
Share
Previous

A Vaccine Plus Antiviral Meds Could Conquer Hepatitis C

Back to News Homepage
Next

Differentiating Between Hepatitis C Genotypes and the IL-28B Genotype

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.